EOCN EoCene Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1595353 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026-06-30), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-30.1%
TTM EPS YoY-182.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-68.2%
ROA-55.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets30.3%
Debt / equity0.00x
Current ratio4.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $4.87M | $2.98M | $3.57M | $12.99M | $27.22M |
| SG&A expense | $3.64M | $3.30M | $3.92M | $4.66M | $5.66M |
| Pretax income | — | $7.52M | $6.91M | $17.87M | -$32.47M |
| Income tax | $0 | — | — | — | — |
| Net income | -$10.31M | -$7.52M | -$6.91M | -$17.87M | -$32.47M |
| EPS (basic) | 2.39 | 8.08 | 30.00 | 127.80 | 19.80 |
| EPS (diluted) | 2.39 | 8.08 | 30.00 | 127.80 | 19.80 |
| Weighted avg. shares (diluted) | 4.31M | 930,822 | 230,795 | 139,682 | 1.64M |
| Balance sheet | |||||
| Cash & equivalents | $3.98M | $4.65M | $2.86M | $2.02M | $2.88M |
| Short-term investments | $7.03M | $7.18M | $7.53M | $11.77M | $31.93M |
| Receivables | — | $672,000 | $480,000 | $825,000 | $1.12M |
| Current assets | $18.63M | $16.12M | $13.24M | $14.72M | $36.05M |
| PP&E, net | — | — | $83,000 | $114,000 | $145,000 |
| Total assets | $18.63M | $18.50M | $16.63M | $16.56M | $36.60M |
| Current liabilities | $2.85M | $2.17M | $2.75M | $3.09M | $5.88M |
| Total liabilities | $2.85M | $2.17M | $2.75M | $3.14M | $6.11M |
| Shareholders' equity | $15.78M | $16.33M | $13.88M | $13.42M | $30.50M |
| Shares outstanding | 822,674 | 1.66M | 573,741 | 1.69M | 25.09M |
| Cash flow statement | |||||
| Operating cash flow | -$6.32M | -$5.88M | -$6.14M | -$18.50M | -$32.89M |
| Capital expenditure | — | — | — | $4,000 | $11,000 |
| Free cash flow | — | — | — | -$18.50M | -$32.90M |
| Investing cash flow | -$3.38M | -$1.11M | $800,000 | $17.56M | $11.46M |
| Financing cash flow | $9.03M | $8.79M | $6.18M | $70,000 | $17.37M |
| Depreciation & amortization | — | $83,000 | $31,000 | $35,000 | $42,000 |
| Stock-based compensation | $546,000 | $531,000 | $892,000 | $1.30M | $1.89M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.